AKT1 and non-small cell lung carcinoma: Given that many AKT inhibitors, including MK-2206, are currently undergoing clincal development, it is of particular importance to determine whether such blockers may have similar effects as that caused by AKT1 siRNA knockdown on NSCLC invasiveness.